Cardiometabolic vigilance in COVID-19 and resource husbandry in resource-challenged times: Clinical practice- based expert opinion.
COVID-19 resource husbandry
Cardiometabolic vigilance
Diabetes mellitus
Hypertension
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
Historique:
received:
24
09
2020
revised:
12
11
2020
accepted:
14
11
2020
pubmed:
15
12
2020
medline:
12
3
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
The ongoing pandemic of coronavirus disease 2019 (COVID-19) is rapidly evolving, thereby posing a profound challenge to the global healthcare system. Cardiometabolic disorders are associated with poor clinical outcomes in persons with COVID-19. Healthcare challenges during the COVID-19 pandemic are linked to resource constraints including shortage of Personal Protective Equipment's (PPE), laboratory tests and medication. In this context, a group of clinical experts discussed the endocrine and cardiology vigilance required in times of COVID-19. Further, the group proposed certain resource husbandry recommendations to be followed during the pandemic to overcome the constraints. The clinical experts discussed and provided their inputs virtually. The expert panel included clinical experts comprising endocrinologists, Consultant Physicians and cardiologists from India. The panel thoroughly reviewed existing literature on the subject and proposed expert opinion. The expert panel put forward clinical practice-based opinion for the management of cardiometabolic conditions including diabetes mellitus and hypertension. As these conditions are associated with poor clinical outcomes, the expert panel recommends that these persons be extra-cautious and take necessary precautions during the ongoing pandemic. Further, experts also provided appropriate, affordable, available and accessible solution to the resource constraint situations in times of COVID-19 pandemic. The clinical expert opinion put forward in this article will serve as a reference for clinicians treating diabetes and cardiovascular disease during the COVID-19 pandemic.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The ongoing pandemic of coronavirus disease 2019 (COVID-19) is rapidly evolving, thereby posing a profound challenge to the global healthcare system. Cardiometabolic disorders are associated with poor clinical outcomes in persons with COVID-19. Healthcare challenges during the COVID-19 pandemic are linked to resource constraints including shortage of Personal Protective Equipment's (PPE), laboratory tests and medication. In this context, a group of clinical experts discussed the endocrine and cardiology vigilance required in times of COVID-19. Further, the group proposed certain resource husbandry recommendations to be followed during the pandemic to overcome the constraints.
METHOD
METHODS
The clinical experts discussed and provided their inputs virtually. The expert panel included clinical experts comprising endocrinologists, Consultant Physicians and cardiologists from India. The panel thoroughly reviewed existing literature on the subject and proposed expert opinion.
RESULTS
RESULTS
The expert panel put forward clinical practice-based opinion for the management of cardiometabolic conditions including diabetes mellitus and hypertension. As these conditions are associated with poor clinical outcomes, the expert panel recommends that these persons be extra-cautious and take necessary precautions during the ongoing pandemic. Further, experts also provided appropriate, affordable, available and accessible solution to the resource constraint situations in times of COVID-19 pandemic.
CONCLUSION
CONCLUSIONS
The clinical expert opinion put forward in this article will serve as a reference for clinicians treating diabetes and cardiovascular disease during the COVID-19 pandemic.
Identifiants
pubmed: 33310177
pii: S1871-4021(20)30479-3
doi: 10.1016/j.dsx.2020.11.014
pmc: PMC7677048
pii:
doi:
Substances chimiques
Blood Glucose
0
Cardiotonic Agents
0
Hypoglycemic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
55-62Informations de copyright
Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors had full access to the articles reviewed in this manuscript, have read and reviewed the final draft of this manuscript and take complete responsibility for the integrity and accuracy of this manuscript. The content published herein solely represents the views and opinions of the authors and does not represent the views or opinion of Sanofi and/or its affiliates. The details published here is an expert opinion and not intended to supplement, nor supersede, the most up to date guidance from international and local health authorities related to the COVID-19 outbreak. No products mentioned in this expert opinion article are indicated for the prevention or treatment of COVID-19.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet Diabetes Endocrinol. 2016 Feb;4(2):148-58
pubmed: 26656292
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):273-276
pubmed: 32283497
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Diabetes Care. 2020 Dec;43(12):2999-3006
pubmed: 32994187
Diabetes Metab Syndr. 2020 May - Jun;14(3):255-256
pubmed: 32248083
Diabetes Metab Syndr. 2020 May - Jun;14(3):247-250
pubmed: 32247212
Circulation. 2005 May 24;111(20):2605-10
pubmed: 15897343
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
J Immunol. 2018 Jan 15;200(2):623-631
pubmed: 29246951
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Pak Med Assoc. 2020 May;70(Suppl 3)(5):S25-S29
pubmed: 32515372
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1355-1360
pubmed: 32755835
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):283-287
pubmed: 32283499
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):797-799
pubmed: 32534432
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
PLoS One. 2011 Apr 25;6(4):e18120
pubmed: 21541017
J Clin Med. 2019 Dec 16;8(12):
pubmed: 31888124
World J Diabetes. 2015 Jul 25;6(8):1073-81
pubmed: 26240704
Diabetes Res Clin Pract. 2020 May;163:108186
pubmed: 32360400
Diabetes Res Clin Pract. 2020 Jun;164:108183
pubmed: 32360697
Respirology. 2019 Jul;24(7):646-651
pubmed: 30761687
J Hum Hypertens. 2020 Jun;34(6):457-467
pubmed: 31484988
Diabetes Care. 2018 Oct;41(10):2127-2135
pubmed: 30104296
Hypertension. 2004 May;43(5):970-6
pubmed: 15007027
Acta Diabetol. 2020 Jul;57(7):779-783
pubmed: 32506195
Obes Med. 2020 Sep;19:100290
pubmed: 32844132
Endocrinology. 2015 Oct;156(10):3559-69
pubmed: 26196539
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1747-1750
pubmed: 32927405
Diabetes Res Clin Pract. 2020 Sep;167:108382
pubmed: 32853686
Diabet Med. 2021 Jan;38(1):e14378
pubmed: 32740972
Front Endocrinol (Lausanne). 2021 Jan 13;11:600439
pubmed: 33519709
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):415-416
pubmed: 32501477
J Assoc Physicians India. 2020 May;68(5):46-49
pubmed: 32610866
Diabetes Metab Syndr. 2020 May - Jun;14(3):241-246
pubmed: 32247211
Clin Endocrinol (Oxf). 2020 Oct;93(4):390-393
pubmed: 32683745
mBio. 2015 Aug 11;6(4):e01120
pubmed: 26265720
Indian Heart J. 2020 May-Jun;72(3):212-213
pubmed: 32405087
Anesth Analg. 2021 Apr 1;132(4):930-941
pubmed: 33093359
J Clin Lipidol. 2020 Jul - Aug;14(4):396-397
pubmed: 32682805
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):513-517
pubmed: 32388331
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):971-978
pubmed: 32610262
Am J Physiol Endocrinol Metab. 2020 Jun 1;318(6):E835-E837
pubmed: 32401039
J Diabetes. 2020 Jul;12(7):556-557
pubmed: 32419360
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):829-831
pubmed: 32540737